Influence of Tumour Physico-chemical Conditions on Interleukin-2-stimulated Lymphocyte Proliferation

Overview

Journal Br J Cancer

Specialty Oncology

Date 1992 Oct 1

PMID 1419598

Citations 17

Authors

D A Loeffler

P L Juneau

S Masserant

Affiliations

Soon will be listed here.

Abstract

The proliferative response of murine lymphocytes to interleukin-2 (IL-2) was examined under physico-chemical conditions present in solid tumours, namely low oxygen and glucose concentrations and acidic pH. Lymphocytes were cultured for four days in 30 U ml-1 IL-2 to simulate serum IL-2 concentrations attainable with high-dose systemic IL-2 therapy. Lymphocyte proliferation was significantly (P < 0.05) reduced by low oxygen concentrations (both anoxia [0% O2] and hypoxia [10%, low glucose (6 mg dl-1), or acidic pH (6.7 or 6.4). Moderate glucose concentration (32 mg dl-1), or neutral pH (7.0) did not impair proliferation. This study indicates that impairment of lymphocyte proliferation by tumour physico-chemical conditions may be a factor in the relatively poor success rate of IL-2/LAK cell immunotherapy.

Citing Articles

Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.

Bida M, Miya T, Hull R, Dlamini Z Front Immunol. 2024; 15:1497522.

PMID: 39712007 PMC: 11659259. DOI: 10.3389/fimmu.2024.1497522.

Improving cancer immunotherapy co-delivering checkpoint blockade and thrombospondin-1 downregulator.

Xiao Q, Li X, Liu C, Jiang Y, He Y, Zhang W Acta Pharm Sin B. 2023; 13(8):3503-3517.

PMID: 37655330 PMC: 10465872. DOI: 10.1016/j.apsb.2022.07.012.

Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.

Semeniuk-Wojtas A, Poddebniak-Strama K, Modzelewska M, Baryla M, Dziag-Dudek E, Syrylo T Cancer Immunol Immunother. 2023; 72(7):1971-1989.

PMID: 36928373 PMC: 10264486. DOI: 10.1007/s00262-023-03376-9.

Tumour-infiltrating lymphocytes: from prognosis to treatment selection.

Brummel K, Eerkens A, de Bruyn M, Nijman H Br J Cancer. 2022; 128(3):451-458.

PMID: 36564565 PMC: 9938191. DOI: 10.1038/s41416-022-02119-4.

Susceptibility for Some Infectious Diseases in Patients With Diabetes: The Key Role of Glycemia.

Chavez-Reyes J, Escarcega-Gonzalez C, Chavira-Suarez E, Leon-Buitimea A, Vazquez-Leon P, Morones-Ramirez J Front Public Health. 2021; 9:559595.

PMID: 33665182 PMC: 7921169. DOI: 10.3389/fpubh.2021.559595.

References

Tannock I, Kopelyan I . Variation of pO2 in the growth medium of spheroids: interaction with glucose to influence spheroid growth and necrosis. Br J Cancer. 1986; 53(6):823-7. PMC: 2001405. DOI: 10.1038/bjc.1986.139. View

FISCHER J, Rockwell S, Martin D . Perfluorochemicals and hyperbaric oxygen in radiation therapy. Int J Radiat Oncol Biol Phys. 1986; 12(1):95-102. DOI: 10.1016/0360-3016(86)90421-9. View

Dvorak H, Dickersin G, Dvorak A, Manseau E, Pyne K . Human breast carcinoma: fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. J Natl Cancer Inst. 1981; 67(2):335-45. View

Ruscetti F, Gallo R . Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes. Blood. 1981; 57(3):379-94. View

GRAY L, CONGER A, Ebert M, HORNSEY S, Scott O . The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953; 26(312):638-48. DOI: 10.1259/0007-1285-26-312-638. View

Hill R, Stanley J . The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res. 1975; 35(5):1147-53. View

Loeffler D, Keng P, Baggs R, Lord E . Lymphocytic infiltration and cytotoxicity under hypoxic conditions in the EMT6 mouse mammary tumor. Int J Cancer. 1990; 45(3):462-7. DOI: 10.1002/ijc.2910450315. View

Oliver R, Crosby D, Nouri A, Scott E, Galazka A . Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancy. Br J Cancer. 1989; 60(6):934-7. PMC: 2247261. DOI: 10.1038/bjc.1989.393. View

Vaupel P, Kallinowski F, Okunieff P . Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989; 49(23):6449-65. View

10.

Mertelsmann R, Welte K . Human interleukin 2: molecular biology, physiology and clinical possibilities. Immunobiology. 1986; 172(3-5):400-19. DOI: 10.1016/S0171-2985(86)80121-8. View

11.

Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S . A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316(15):889-97. DOI: 10.1056/NEJM198704093161501. View

12.

Eggermont A, Steller E, Ottow R, Matthews Jr W, Sugarbaker P . Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells. J Natl Cancer Inst. 1987; 79(5):983-90. View

13.

Rotin D, Robinson B, Tannock I . Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. Cancer Res. 1986; 46(6):2821-6. View

14.

Rosenberg S, Mule J, Spiess P, Reichert C, Schwarz S . Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985; 161(5):1169-88. PMC: 2187617. DOI: 10.1084/jem.161.5.1169. View

15.

Vaage J, Pepin K . Morphological observations during developing concomitant immunity against a C3H/He mammary tumor. Cancer Res. 1985; 45(2):659-66. View

16.

Bhan A, DesMarais C . Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. J Natl Cancer Inst. 1983; 71(3):507-16. View

17.

Lotze M, Line B, Mathisen D, Rosenberg S . The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol. 1980; 125(4):1487-93. View

18.

Tannock I . Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation. Cancer Res. 1982; 42(12):4921-6. View

19.

Vaupel P, Frinak S, BICHER H . Heterogeneous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma. Cancer Res. 1981; 41(5):2008-13. View

20.

Gullino P, Clark S, Grantham F . THE INTERSTITIAL FLUID OF SOLID TUMORS. Cancer Res. 1964; 24:780-94. View